AstraZeneca (AstraZeneca) NonCurrent Deferred Liabilities

: $0 Mil (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

AstraZeneca's non-current deferred liabilities for the quarter that ended in Dec. 2023 was $0 Mil.

AstraZeneca NonCurrent Deferred Liabilities Historical Data

The historical data trend for AstraZeneca's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

NonCurrent Deferred Liabilities

AstraZeneca Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
NonCurrent Deferred Liabilities																-	-	-	-	-

AstraZeneca NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of AstraZeneca's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca (AstraZeneca) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

AZNCF:USA AZN:Sweden AZNN:Mexico AZNl:UK AZN:UK ZEGA:Germany ZEG:Germany ZEG:Germany ZEG:Germany ZEGA:Germany ZEG:Germany A1ZN34:Brazil

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.